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Mutational screening of newly diagnosed multiple
myeloma patients by deep targeted sequencing
Multiple myeloma (MM) is a hematologic neoplasm
that develops after transformation and excessive growth
of plasma cells in the bone marrow. MM is characterized
by heterogeneous genetic abnormalities and an extensive
range of clinical outcomes.1,2 The marked variability of
responses and the limited clinical prognostic value of the
current genetic information justify the need to identify
new biomarkers of response and develop personalized
medicine strategies.3 The recent introduction of next-gen-
eration sequencing technologies has considerably
advanced our understanding of the biological features of
MM.4-6 Accordingly, we used a targeted deep sequencing
panel, applying the highest read depth to date, to detect
minor subclones and evaluated their impact on response
to treatment. We also integrated these data with the clin-
ical features of a very homogeneous cohort of patients to
unearth new patterns of genetic alterations and gain new
insights into the complexity of the clonal and subclonal
architecture of MM.
We analyzed 79 tumor samples from newly diagnosed
MM patients enrolled in the GEM10MAS65 clinical trial
(registered at www.clinicaltrials.gov as #NCT01237249).7
This phase II study enrolled patients older than 65 years,
and randomly assigned them to one of two treatment
arms: sequential melphalan/prednisone/bortezomib
(MPV) followed by lenalidomide/low-dose dexametha-
sone (Rd), or alternating MPV with Rd. This clinical trial
was carried out in compliance with the Helsinki
Declaration: it was approved by the appropriate research
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Figure 1. Mutated genes and parallel
clonal evolution. (A) Fifty-four genes
were mutated in 79 newly diagnosed
MM patients. KRAS, DIS3, NRAS,
BRAF and TP53 mutations accounted
for 42% of all the mutations. (B) MAX
(right and up) and DIS3 (left and down)
showed concomitant mutations within
the same patient. The proximity
between subclonal mutations enabled
us to detect that variants were in differ-
ent sequencing reads, indicating a
possible parallel subclonal evolution.  
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Ethics Committees and all participants provided written
informed consent before inclusion. The median time to
progression of this cohort of patients was 26.4 months
and the median follow up was 31.5 months. Plasma cells
were enriched from bone marrow aspirates using anti-
CD138+ immunomagnetic beads obtaining a purity high-
er than 85% in all cases and only 20 ng of DNA were
used for library construction. The panel screens 77 genes
that are frequently mutated in MM, including those relat-
ed to critical pathophysiological pathways, genes associ-
ated with drug resistance, or those targetable by molecu-
lar drugs (Online Supplementary Table S1).8-10 The average
coverage depth for CD138+ and CD138– samples was
1600 × and 900 ×, respectively. The minimum coverage
of the detected variants was 20 ×, and the average cover-
age was 370 ×. We applied two different bioinformatics
pipelines developed by Thermofisher (Ion reporter 5.0)
and by the Spanish National Cancer Research Center
(Rubioseq, http://rubioseq.bioinfo.cnio.es/).11 We also
sequenced 11 germline fractions available to confirm that
most of the germinal variants had been correctly exclud-
ed by our conservative filter criteria. 
We identified 168 non-synonymous missense/non-
sense/stop-loss single variants, of which 81 (48%) were
predicted to be pathogenic by SIFT and PolyPhen-2, and
61 (36%) have been described in the COSMIC database.
Eighty-five percent of patients harbored at least one
mutation, with there being a median of 2.1 mutations per
patient. Mutations were detected in 53 genes, although
the following five genes accounted for 42% of the total
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Figure 2. Clonal and subclonal heterogeneity and
variant read frequency distributions. (A) Fifty per-
cent of mutations (85/168) had a variable read fre-
quency (VRF) <25%, and almost half of them
(46/168) had a VRF <10%. These values highlight
the importance of detecting variants at very low fre-
quencies in newly diagnosed patients. (B)
Distribution of the detected variants in the most
frequently mutated genes. The number of patients
harboring the mutations is indicated below the
name of the gene. DIS3 was the only gene in which
a mutation VRF >50% was found.
A
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number of mutations: KRAS (21.5% of patients), DIS3
(19%), NRAS (16.5%), BRAF (10.1%) and TP53 (8.8%)
(Figure 1A). The RAS pathway was the most recurrently
mutated, present in 48% (39/79) of patients. Seventy-
two and 100% of KRAS and NRASmutations, respective-
ly, were detected at the hotspot codons 12, 13 and 61,
and the targetable BRAF V600E activating mutation was
detected in one patient. KRAS and BRAF mutations were
co-existent in three patients, while RAS was always
mutated exclusively. NF-kB was the second most fre-
quently mutated pathway in our cohort, accounting for
15% of all mutations; mutations were found in the genes
of 25% of the patients (19/79), including the adapter sig-
naling genes TRAF3 (1 nonsense and 4 missense) and
TRAF2 (3 missense). All were predicted to be pathogenic
by SIFT and PolyPhen-2. Other pathways that were
altered in our cohort were MYC, in 11% of patients
(9/79), and Cereblon and Cyclin, each found in 9% of
patients (7/79). Multiple mutations in the same gene
were observed in 12 patients, affecting DIS3 (n=4), KRAS
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Figure 3. Negative impact of genetic alterations on progression-free survival (left) and overall survival (right). (A) Mutations in TP53. (B) Mutations in the









(n=3), NRAS (n=2), MAX (n=1), TRAF3 (n=1) and TP53
(n=1) genes. The MAX mutations were missense and
were located at the known MAX hotspots E32V, R35L
and R36K. All three MAX mutations were found to be
subclonal, with variant read frequencies (VRF) of 26%,
21% and 10%, respectively. Interestingly, due to the
proximity between mutations it was possible to confirm
that each variant was located on a different sequencing
read, with no read containing more than one mutation
(Figure 1B). Since this patient had a diploid karyotype,
the entire tumor was affected by the mutations in the
MAX gene, but with a parallel evolution of the three dif-
ferent subclones. The same finding was made in one of
the patients who harbored multiple mutations in DIS3
(Figure 1B); in this case, the two D487H and D479E
hotspot mutations were subclonal, with a VRF of 4% and
21%, respectively, and presented exclusively in different
reads. Our cohort of patients revealed a broad VRF land-
scape, with 50% of variants (85/170) having a VRF below
25% and 27% (46/170) having a VRF below 10% (Figure
2A). The VRF of most of the mutations in KRAS, BRAF,
NRAS and TP53was lower than 40%, while that of DIS3
mutations showed a broader range (2% to 85%) (Figure
2B). The DIS3 gene had the largest number of low VRF
mutations (5/20), all of which were considered to be
pathogenic by SIFT and PolyPhen-2, and four of which
were located in hotspots of the catalytic RNB domain
(Online Supplementary Figure S1D). 
We also evaluated the impact on survival of each indi-
vidual mutated gene, and of genes grouped according to
their pathways. No significant impact on survival was
observed for KRAS, NRAS, BRAF or DIS3 genes or for the
RAS and NF-kB pathways. The existence of multiple
mutations in the same gene or the number of subclonal
mutations (<40% VRF) did not affect patients’ survival.
However, TP53 mutations were associated with a nega-
tive impact on progression-free survival and overall sur-
vival (P=0.019 and P=0.004, respectively) (Figure 3A).
Patients with mutations in the Cereblon pathway had
significantly shorter progression-free survival and overall
survival (P=0.040 and P<0.0001, respectively) (Figure 3B).
We also noted a negative impact on progression-free sur-
vival and overall survival as a function of the number of
mutations: patients with more than three mutations (>1
mutation per 61 kb of DNA analyzed) relapsed and died
prematurely (P=0.033 and P=0.002, respectively) (Figure
3C). We performed multivariate survival analysis using a
Cox regression model with the Akaike Information
Criterion technique for the selection of demographic and
cytogenetic variables. The variables selected to build the
model were International Staging System score, Eastern
Cooperative Oncology Group score and the patient’s age.
We found a significant negative impact on survival for
TP53 mutations (progression-free survival: hazard ratio,
3.68; 95% confidence interval: 1.45–9.29, P=0.005; over-
all survival: hazard ratio, 9.07; 95% confidence interval:
2.78–9.57, P=0.0002). 
The genes and pathways found to be most frequently
mutated in this study are consistent with those in previ-
ous reports (KRAS 21% versus 21%, NRAS 18% versus
16%, BRAF 7% versus 8% and TP53 8% versus 8%).6,9 The
exception was DIS3, for which the mutational incidence
increased from 9% to 19% due to the deep coverage
which enabled the detection of a higher number of sub-
clonal mutations (5/20). In addition, the VRF of mutated
RAS genes (<50% in all cases) supports the hypothesis
that newly diagnosed MM patients who are not exposed
to selective pressure by a therapy are more likely to har-
bor subclonal than clonal RAS mutations.5 The detection
of minor subclones has allowed the identification of a
subgroup of patients with poor outcome who would not
have been identified by their cytogenetic profile or clini-
cal manifestation, including those negative for del(17p)
but positive for TP53 mutations.12 Considering the detec-
tion threshold in whole-genome and whole-exome
sequencing studies, very useful genetic information
might be being overlooked. Additionally, the recent dis-
covery that Cereblon is essential for the anti-MM activity
of immunomodulatory drugs13-15 is especially relevant
here because patients enrolled in the GEM10MAS65 trial
were all treated with lenalidomide, suggesting that
downstream genes such as IKZF1, IKZF2, IRF4 and MYC
should be additionally studied when biomarkers of
lenalidomide resistance need to be identified. 
In conclusion, this is the first prospective study
addressing the role of targeted sequencing in a highly
homogeneous series of elderly, newly diagnosed MM
patients treated within a clinical trial. Despite the limited
number of samples included in the study, the next-gener-
ation sequencing strategy used here was capable of
detecting mutations in purified plasma cells in most
patients. The affordability of next-generation sequencing
together with the small sample requirement offers an
excellent opportunity to introduce personalized medicine
protocols into clinical practice and also to intensify the
search for new biomarkers and therapeutic targets to
improve treatment selection and survival of MM
patients.
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